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Purpose
The purpose of this study was to develop Korean versions of the National Comprehensive
Cancer Network/Functional Assessment of Cancer Therapy (NCCN-FACT) Ovarian Symptom
Index-18 (NFOSI-18) and FACT/Gynecologic Oncology Group (FACT-GOG) Neurotoxicity 
4-item (NTX-4), evaluating their reliability and reproducibility. 
Materials and Methods
In converting NFOSI-18 and NTX-4, the following steps were performed: forward translation,
backward translation, expert review, pretest of preliminary format, and finalization of Korean
versions (K-NFOSI-18 and K-NTX-4). Patients were enrolled from six institutions where each
had completed chemotherapy for ovarian, tubal, or peritoneal cancer at least 1 month earlier.
In addition to demographics obtained by questionnaire, all subjects were assessed via 
K-NFOSI-18, K-NTX-4, and a Korean version of the EuroQoL-5 Dimension. Internal structural
validity and reliability were evaluated using item internal consistency, item discriminant 
validity, and Cronbach's . To evaluate test-retest reliability, K-NFOSI-18 and K-NTX-4 were
readministered after 7-21 days, and intraclass correlation coefficients (ICCs) were calcu-
lated.
Results
Of the 250 women enrolled during the 3-month recruitment period, 13 withdrew or did not
respond, leaving 237 (94.8%) for the analyses. Mean patient age was 54.3±10.8 years.
Re-testing was performed in 190 patients (80.2%). The total K-NFOSI-18 and K-NTX-4 scores
were 49 (range, 20 to 72) and 9 (range, 0 to 16), respectively, with high reliability (Cron-
bach's =0.84 and 0.89, respectively) and reproducibility (ICC=0.77 and 0.84, respectively)
achieved in retesting.  
Conclusion
Both NFOSI-18 and NTX-4 were successfully developed in Korean with minimal modification.
Each Korean version showed high internal consistency and reproducibility. 
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Introduction
In the United States alone, approximately 22,440 new cases
of ovarian cancer and 14,080 related deaths were recorded
for 2015 [1]. The incidence of ovarian cancer, which is now
1.5% annually in Korea [2], continues to climb. Ovarian can-
cer is typically diagnosed at an advanced stage of the disease
(in more than 70% of patients). Relapse is common after first-
line treatment, and prolonged therapeutic intervention is
usually required [3,4]. Quality of life (QoL) is thus included
with survival as an endpoint in clinical trials. However, there
is scant evidence from the numerous studies conducted to
date that palliative chemotherapeutic regimens administered
for platinum-resistant ovarian cancer actually improve
symptom control [5].
The National Comprehensive Cancer Network (NCCN)–
Functional Assessment of Cancer Therapy (FACT) Ovarian
Symptom Index-18 (NFOSI-18), developed in the United
States in 2011, helps assess symptoms that patients with 
advanced ovarian cancer may experience [6]. It is based on
three subscales: disease-related symptoms, treatment-related
symptoms, and general function/well-being Preliminary 
reliability indicators suggest good internal consistency, with
a Cronbach's  of 0.80. NFOSI-18 and its subscales have
demonstrated significant positive associations with perform-
ance status. In a recent study validating the content of
NFOSI-18, approximately 90% of participants rated each item
as clear and understandable [7]. However, NFOSI-18 lacks a
neurotoxicity subscale, and 18% of patients rendered spon-
taneous reports of neuropathy during open-ended question-
ing regarding symptoms. The FACT/Gynecology Oncology
Group (GOG) Neurotoxicity 4-item (NTX-4) survey is a val-
idated tool for assessing platinum/paclitaxel-induced neu-
rologic symptoms [6,7].
The Korean Gynecology Oncology Group (KGOG) is con-
sidering participating in international GOG collaborative tri-
als that use NFOSI-18 and NTX-4. As there are currently no
validated Korean versions of these questionnaires, develop-
ment and evaluation of Korean versions (K-NFOSI-18 and 
K-NTX-4) are required. Accordingly, the goals of this study
were to adapt the existing NFOSI-18 and NTX-4 for Korean
women and to evaluate the reliability and reproducibility of
these adaptations. 
Materials and Methods
1. Study population
This multicenter study, involving six institutions (Seoul
National University Hospital, National Cancer Center, Seoul
National University Bundang Hospital, Asan Medical Cen-
ter, Samsung Medical Center, and Gangnam Severance Hos-
pital), was conducted between August 2016 and October
2016. Participants were recruited by the respective Depart-
ments of Obstetrics and Gynecology and were consecutively
enrolled. Inclusion criteria were as follows: (1) age 18 years
or older; (2) diagnosis of ovarian, fallopian tube, or primary
peritoneal cancer; (3) prior treatment with adjuvant chemo-
therapy or radiotherapy; and (4) ability to speak and under-
stand the Korean language. Chemotherapeutic treatment
within the 1 month prior to study enrolment, inability to 
understand the questionnaires, and refusal to participate
were the criteria for exclusion. 
The collected patient data included demographic variables
(age, marital status, educational level, state of employment,
family income, smoking/drinking habits, exercise activity,
menopausal status, height, and weight) and disease charac-
teristics (cancer stage, grade, duration of treatment, and 
recurrence status). To assess test-retest reliability, the ques-
tionnaires initially administered to patients were repeated in
the same subjects 7-21 days later. All patients were asked to
participate in this retesting. The Korean version of the Euro-
QoL-5 Dimension (K-EQ5D) questionnaire was also admin-
istered at the same time as the initial administration of
K-NFOSI-18 and K-NTX-4 [8]. 
2. NFOSI-18 and NTX-4 questionnaires
Following baseline interviews, patients completed a 
Korean version of NFOSI-18 (K-NFOSI-18). NFOSI-18 con-
sists of 18 items with four dimensions: disease-related symp-
toms, physical (nine items); disease-related symptoms,
emotional (one item); treatment side effects (five items); and
function/well-being (three items). Each item is scored from
0 (“not at all”) to 4 (“very much”) [6].
Following baseline interviews, patients also completed a
Korean version of NTX-4 (K-NTX-4) [9]. NTX-4 consists of
these four items: numbness or tingling in the feet, numbness
or tingling in the hands, discomfort in the feet, and discom-
fort in the hands. Each item is scored from 0 (“not at all”) to
4 (“very much”).
K-NFOSI-18 and K-NTX-4 were developed through for-
ward translation, backward translation, and discussion. Two
independent researchers translated K-NFOSI-18 and K-NTX-
4 into Korean, and a bilingual (English and Korean) 
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researcher performed backward translation. The first Korean
version was reviewed by a scholar of Korean literature. In
September 2016, ten patients with ovarian cancer partici-
pated in a pilot test of both surveys at the Seoul National Uni-
versity Hospital. Based on the pilot results, item 13 (“I am
bothered by side effects of treatment”) was modified because
the question was incomprehensible in the Korean language
for two patients. Once revised, the finalized versions were
administered to study participants at each hospital as inter-
viewer-assisted self-report questionnaires.
3. Data analysis
Categorical variables were expressed as frequency (%) and
continuous variables as mean±standard deviation or median
(range). To test the validity and reliability of questionnaires,
item-level and dimension-level analyses were performed. In
item-level evaluations, item internal consistency (IIC), and
item discriminant validity (IDV) served as indices of internal
structural validity. IIC reflects correlation between an item
and all companion items in the same dimension, whereas
IDV measures how well an item correlates with items in the
same dimension, compared with items in other dimensions.
In dimension-level evaluations, reliability was evaluated via
Cronbach's , based on the total score or dimension score (in
dimensions with more than two items). Reproducibility was
evaluated through test-retest reliability and indicated by the
intraclass correlation coefficient (ICC). The NFOSI-18 scoring
guidelines ver. 2 (S1 Fig.) and NTX scoring guidelines ver. 4
(S2 Fig.) were used to calculate dimension scores. Responses
were inverse-coded in K-NFOSI-18 and K-NTX-4, except for
five questions in K-NFOSI-18 (C3, GF5, BMT5, GF3, and
Table 1. Demographic and disease characteristics of study
population 
(Continued)
Characteristic No. (%) (n=237)
Age, mean±SD (yr) 54.27±10.75
Marital status
Single 26 (11.0)
Married 191 (80.6)
Divorced 9 (3.8)
Widowed 11 (4.6)
Educational level (missing=2)
Elementary school or less 17 (7.3)
Middle school 20 (8.5)
High school 72 (30.6)
College or above 126 (53.6)
Employment (missing=1)
Employed 67 (28.4)
Unemployed 169 (71.6)
Family income (1,000 won/mo) (missing=10)
< 200 47 (20.7)
200-300 43 (18.9)
300-400 41 (18.1)
400-500 39 (17.2)
> 500 57 (25.1)
Smoking 
Current 3 (1.3)
Past 11 (4.6)
Nonsmoker 223 (94.1)
Drinking (missing=1)
> 4 times/wk 0 (
2-3 times/wk 3 (1.3)
Once/wk 17 (7.2)
Nondrinker 216 (91.5)
Regular exercise
Yes 130 (54.9)
No 107 (45.1)
Menopausal status
Yes 216 (91.1)
No 21 (8.9)
Height, mean±SD (cm) 157.88±6.17
Weight, mean±SD (kg) 57.86±8.12
Treatment duration (missing=6), 5 (1-38)
median (min-max, mo)
FIGO stage
1 81 (34.6)
2 30 (12.8)
3 90 (38.5)
4 27 (11.5)
Unknown 6 (2.6)
Table 1. Continued
SD, standard deviation; min, minimum; max, maximum;
FIGO, International Federation of Gynecology and Obstet-
rics; BEP, bleomycin+etoposide+cisplatin.
Characteristic No. (%) (n=237)
Grade (missing=15)
1 20 (9.0)
2 54 (24.3)
3 137 (61.7)
4 11 (5.0)
Chemotherapy regimens
Paclitaxel+carboplatin 230 (97.0)
BEP 7 (3.0)
Recurrence or metastasis
Yes 61 (25.7)
No 176 (74.3)
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GF7), so that higher scores would represent better perform-
ance in both scores. Spearman’s correlation coefficient was
calculated to evaluate the external validity of K-NFOSI-18,
K-NTX-4, and K-EQ5D scores. Differences in K-NFOSI-18
and K-NTX-4 scores according to recurrence status were
compared using the Wilcoxon rank sum test to measure dis-
criminant validity. All reported p-values were two-sided,
with statistical significance set at p < 0.05. Statistical analyses
were performed using R project freeware (ver. 3.3.2).
4. Ethical statement
The institutional review boards of each contributing insti-
tution (Seoul National University Hospital: IRB#1607-206-
782, National Cancer Center: IRB#2016-0194, Seoul National
University Bundang Hospital: IRB#1608-358-305, Asan Med-
ical Center: IRB#2016-0831, Samsung Medical Center: IRB#
2016-07-087, and Gangnam Severance Hospital: IRB#3-2016-
0163) approved the study protocol, and all participants pro-
vided written informed consent.
Results
During the 3-month recruitment period, 250 women were
enrolled in the study. The main analyses were limited to 237
patients (94.8%), after excluding withdrawals and non-
responses. Re-testing without missing data was conducted
in 190 patients (80.2%). Table 1 displays socio-demographic
and clinical characteristics of the study subjects. The mean
age was 54.27±10.75 years, with most patients registered as
non-smokers, non-drinkers, and menopausal. More than half
of the patients (55%) exercised regularly. The median dura-
tion of treatment was 5 months. Paclitaxel-carboplatin based
chemotherapy was received by 97% of patients. Cancer
stages were distributed as follows: stage 1, 81/237 (34.6%);
stage 2, 30/237 (12.8%); stage 3, 90/237 (38.5%); and stage 4,
27/237 (11.5%). The overall rate of cancer relapse was 25.7%. 
Each item in K-NFOSI-18 and K-NTX-4 was determined
according to the time of occurrence (i.e., within the previous
7 days). Median total scores for first-round survey adminis-
tration were 49 (range, 20 to 72) and 9 (range, 0 to 16), respec-
tively. The most frequent symptom was nausea (100%),
followed by cramping (99.6%), vomiting (99.6%), swelling of
the stomach area (97.9%), feeling ill (97.9%), lack of energy
(97.9%), pain (97%), constipation (96.6%), and skin problems
(95.7%). Numbness or tingling sensations affected the hands
(91.9%) more commonly than the feet (77.6%).
Table 2 provides a summary of structural validity, reliabil-
ity, and reproducibility of K-NFOSI-18 and K-NTX-4. Ta
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K-NFOSI-18 exhibited high internal consistency and reliabil-
ity (Cronbach's =0.84), with good reproducibility in re-test-
ing: disease-related symptoms, physical (ICC=0.75); disease-
related symptoms, emotional (ICC=0.67); treatment side 
effects (ICC=0.59); function/well-being (ICC=0.53); and total
score (ICC=0.77). K-NTX-4 also showed high reliability
(Cronbach's =0.89) and reproducibility (ICC=0.84).
Table 3 lists the Spearman correlation coefficients for com-
parisons among K-NFOSI-18, K-NTX-4, and K-EQ5D scores
for the first-round survey administration. There was weak
positive correlation between total K-NFOSI-18 and K-NTX-
4 scores (Spearman correlation coefficient=0.348) (Table 3).
K-EQ5D items showed weak-to-moderate correlation with
K-NFOSI-18 and K-NTX-4 (Tables 4 and 5). K-EQ5D incor-
Table 3.  Correlation between K-NFOSI-18 and K-NTX-4 scores
Dimension NTX 1 NTX 2 NTX 3 NTX 4 K-NTX-4 total
DRS-Physical (0-36) 0.291 0.217 0.275 0.281 0.308 
DRS-Emotional (0-4) 0.143 0.120 0.066 0.091 0.121 
Treatment side effects (0-20) 0.340 0.266 0.314 0.222 0.330 
Function/Well-being (0-12) 0.250 0.231 0.266 0.219 0.272 
Total NFOSI-18 score (0-72) 0.331 0.274 0.317 0.281 0.348 
Data are Spearman’s correlation coefficients for all dimension values. K-NFOSI-18, Korean versions of the National Com-
prehensive Cancer Network/Functional Assessment of Cancer Therapy (NCCN-FACT) Ovarian Symptom Index-18; K-NTX-
4, FACT/Gynecologic Oncology Group (FACT-GOG) Neurotoxicity 4-item; DRS, disease-related symptoms.
Table 4.  Correlation between K-EQ5D items and VAS with K-NFOSI-18 scores
Dimension DRS- DRS- Treatment Function/ K-NFOSI-18Physical Emotional side effects Well-being total
Mobility –0.292 –0.102 –0.209 –0.320 –0.324  
Self-care –0.252 –0.091 –0.190 –0.294 –0.295 
Usual activities –0.381 –0.245 –0.354 –0.444 –0.480 
Pain/Discomfort –0.421 –0.121 –0.232 –0.250 –0.374 
Anxiety/Depression –0.351 –0.487 –0.376 –0.255 –0.434 
VAS 0.510 0.357 0.301 0.313 0.500 
Data are Spearman’s correlation coefficients for all dimension values. K-EQ5D, Korean EuroQoL-5 Dimension survey; VAS,
Visual Analogue Scale; K-NFOSI-18, Korean versions of the National Comprehensive Cancer Network/Functional Assess-
ment of Cancer Therapy (NCCN-FACT) Ovarian Symptom Index-18; DRS, disease-related symptoms.
Table 5.  Correlation between K-EQ5D items and VAS with K-NTX-4 scores
Dimension NTX 1 NTX 2 NTX 3 NTX 4 K-NTX-4 total
Mobility –0.399 –0.383 –0.352 –0.475 –0.471  
Self-care –0.237 –0.205 –0.277 –0.263 –0.287 
Usual activities –0.340 –0.370 –0.369 –0.416 –0.435 
Pain/Discomfort –0.423 –0.371 –0.409 –0.460 –0.482 
Anxiety/Depression –0.168 –0.134 –0.200 –0.128 –0.178 
VAS 0.314 0.363 0.317 0.422 0.411 
Data are Spearman’s correlation coefficients for all dimension values. K-EQ5D, Korean EuroQoL-5 Dimension survey; VAS,
Visual Analogue Scale; K-NTX-4, FACT/Gynecologic Oncology Group (FACT-GOG) Neurotoxicity 4-item.
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porates five dimensions with three levels, generating one
continuous score (Visual Analogue Scale). Correlation coef-
ficients were negative because lower scores imply better sta-
tus in K-EQ5D, whereas lower scores imply poorer status in
K-NFOSI-18 and K-NTX-4 (Tables 4 and 5).
Discussion
In the present study, we developed reliable and repro-
ducible Korean versions of standard NFOSI-18 and NTX-4
surveys (Cronbach's =0.84 and 0.89, respectively; ICC=0.77
and 0.84, respectively). Furthermore, there was positive cor-
relation between total K-NFOSI-18 and K-NTX-4 scores.
A variety of validation tools are used to measure QoL in
gynaecologic cancers, but they do not always align with the
specific problems of patients with ovarian cancer [10,11]. 
Recently, ovarian cancer trials have added QoL as a second-
ary end-point [12,13], so tailoring questionnaires to specific
countries for international use is assuming greater impor-
tance. The clinical impact of QoL is addressed in only 30% of
such queries because of methodologic issues [14], underscor-
ing the need to adopt Korean versions of the NFOSI-18 and
NTX-4. 
In this study, > 95% of patients exhibited disease-related
symptoms in the physical realm; these were more common
than emotional symptoms. In the dimension of treatment
side effects, patients consistently experienced nausea (100%)
and vomiting (99.6%). However, by adding neurologic
symptoms to the body of questions, we found that most 
patients (87%) experienced neurotoxicity as well, more often
involving the hands than the feet. Although patients were
excluded if they received chemotherapy within 1 month of
study onset, it seems to contain a large number of patients
currently on the chemotherapy course.
A distinct advantage of the present study is its large-scale,
multicenter design. Furthermore, the short time required to
complete the questionnaires (< 10 minutes) greatly encour-
aged compliance. Hence, the combined instrument (K-NFO-
SI-18 and K-NTX-4) may not be burdensome for patients.
Although the ICC for constipation scoring in the K-NFOSI-
18 was < 0.80, ICCs for most subscales and single items dis-
played good reproducibility. With ICC values of 0.7 or
higher, two repeated test results may be expected to lie with
a probability of 95%. These findings indicate that the Korean
version of NFOSI-18 is a stable adaptation. In discriminant
validity analysis, a result greater than 0.85, indicates that the
two constructs overlap greatly and are likely measuring the
same thing. In our study, IDV values were 88.9 to 100, indi-
cating that K-NFOSI-18 and K-NTX-4 have good discrimi-
nant validity.
Previous studies have reported worse QoL in patients with
disease recurrence [4,15-17]. However, other investigators
have shown opposite results, generating controversy [18,19].
The present study confirmed (as expected) that patients with
(vs. without) recurrence differed in terms of function/well-
being scores. However, other dimensions, including disease-
related symptoms and treatment side effects, showed no
significant relationship with disease status.
Some study limitations are acknowledged. We did not 
assess changes in QoL over time, during chemotherapeutic
cycles, or during multiple treatment cycles and courses. In
addition, no patients hospitalized after surgery or chemo-
therapy were similarly surveyed to generate comparative 
results. Another limitation was the possibility that patients
with symptoms may have been more likely to agree to par-
ticipate in the study, leading to over-estimation of symptom
rates. However, we chose the same inclusion criteria as those
used in the study for which NFOSI-18 was first applied.
In conclusion, Korean versions of the NFOSI-18 and NTX-
4 questionnaires were successfully developed and demon-
strated high internal consistency and reproducibility in the
test population. Few modifications were required. Further
efforts are required to address their reliability and validity
in clinical research.
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